Navigation Links
Shell Transfers Its Codexis Shares to Raizen
Date:6/2/2011

REDWOOD CITY, Calif., June 2, 2011 /PRNewswire/ -- Codexis, Inc. (Nasdaq: CDXS) today announced that Equilon Enterprises LLC, a wholly owned subsidiary of Royal Dutch Shell plc, has completed the transfer of approximately 5.6 million shares of Codexis common stock (which represents approximately 15.7% of Codexis' total outstanding shares) to Raizen Energia Participacoes S.A., a Brazil-based biofuels joint venture between Shell and Cosan Limited.  This transfer occurred as part of the closing of the joint venture.  As a result of the share transfer, Raizen is now Codexis' largest stockholder, and, under an existing stockholder agreement, has the right to appoint a representative to Codexis' Board of Directors.

"We look forward to the opportunity to work with Raizen in development of biofuels," said Alan Shaw, Ph.D., Codexis President and Chief Executive Officer.  "With access to feedstocks and experience in ethanol production, Raizen has the potential to accelerate future commercialization of renewable fuels."

About Raizen

Raizen is a $12 billion joint venture with annual production capacity of over 2 billion liters of ethanol, making it the third-largest fuels company in Brazil. It has a retail network of 4,500 fuel stations, 24 sugar mills and an installed capacity of 900MW of electric energy from sugar cane bagasse.

About Codexis

Codexis is a clean technology company. Codexis develops optimized biocatalysts that make industrial processes faster, cleaner and more efficient. Codexis' technology is commercialized with leading global pharmaceutical companies and in development for advanced biofuels with Shell and in carbon capture. Other potential markets include chemicals and water treatment. For more information, see www.codexis.com.

Forward-Looking Statements

This press release contains forward-looking statements relating to the company's opportunities to develop biofuels with Raizen and Raizen's potential to accelerate future commercialization of renewable fuels. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results.  Factors that could materially affect actual results include the timing, cost and feasibility of the production and commercialization of biofuels derived from cellulose.  Other factors can be found in Codexis' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 6, 2011, including under the caption "Risk Factors."  Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:

Media:  Lyn Christenson, lyn.christenson@codexis.com, 650.421.8144 or Saskia Sidenfaden, ssidenfaden@mww.com, 212.827.3771
Investors:  Henk Adriaenssens, ir@codexis.com, 650.421.8331


'/>"/>
SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ben-Gurion U. research leads to improved calcium supplement derived from crustacean shells
2. UCSB physicists challenge classical world with quantum-mechanical implementation of shell game
3. First high-resolution images of bone, tooth and shell formation
4. Spherix Transfers Stock Listing to Nasdaq Capital Market
5. Codexis Reports First Quarter 2011 Results
6. Former Senator Byron Dorgan Elected to Codexis Board
7. Codexis Reports Fourth Quarter and Full Year 2010 Results
8. Codexis Grows Revenue 35 Percent in Third Quarter; Raises 2010 Outlook
9. Codexis Names Vonnie Estes to New Technology Strategic Planning VP Role
10. Codexis R&D Productivity Panels Also Used By Roche
11. Codexis Names Lori Giver VP Systems Biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... ... largest privately-held contract pharmaceutical development and manufacturing organisation, today announced the ... company combining a leading CRO and the industry’s only Contract Commercial Organization ...
(Date:12/6/2016)... ... December 06, 2016 , ... Clinical Supplies ... has acquired the assets of Theorem Clinical Research - Clinical Supplies ("TCS"). ... trial drug packaging, labeling, storage, reconciliation, and distribution for pharmaceutical trials across ...
(Date:12/6/2016)... 6, 2016  The Texas Medical Center ... (HISA) today announced the establishment of a new ... Australia and the Texas Medical ... HISA and the Texas Medical Center, with ... create a global health innovation ecosystem where emerging technologies ...
(Date:12/5/2016)... Research and Markets has announced the addition of ... to their offering. ... , This report describes ... such as proteomics and metabolomics. Molecular diagnostics technologies are used for ... biomarker. Currently the most important applications of biomarkers are ...
Breaking Biology Technology:
(Date:11/24/2016)... , Nov. 23, 2016 Cercacor today introduced ... and their trainers non-invasively measure hemoglobin, Oxygen ... Rate, and Respiration Rate in approximately 30 seconds. Smaller ... easy and immediate access to key data about their ... a training regimen. Hemoglobin carries oxygen ...
(Date:11/22/2016)... 2016   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that the company ... Life Sciences Awards as "Most Outstanding in eClinical ... year of recognition and growth for MedNet, which has ... iMedNet ™ , MedNet,s flagship ...
(Date:11/19/2016)... , Nov. 18, 2016 Securus Technologies, a ... for public safety, investigation, corrections and monitoring, announced today ... competitor, ICSolutions, to have an independent technology judge determine ... most modern high tech/sophisticated telephone calling platform, and the ... that they do most of what we do – ...
Breaking Biology News(10 mins):